AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

AstraZeneca's oncology sales jump 18% in second-quarter 2025, fueled by key drugs and new launches like Truqap and Datroway.

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has granted priority review for its immunotherapy drug Imfinzi for some cancer forms. The Cambridge, England ...

AstraZeneca’s Imfinzi (durvalumab) has been granted priority review by the US Food and Drug Administration (FDA) to treat early-stage gastric cancer. The decision specifically applies to patients with ...

1 Imfinzi (durvalumab) Product Monograph,. AstraZeneca Canada Inc., July 17, 2025. 2 Powles T, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Health Canada has granted a Notice of Compliance (NOC) for Imfinzi® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and ...

AstraZeneca (LSE:AZN) recently reported robust earnings results, with significant year-over-year increases in sales, revenue, and net income, and also declared a dividend increase. These developments ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) in adults with advanced or unresectable hepatocellular carcinoma (HCC). The ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...